Anchor Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.00 M
- Company Age 49 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.13 Cr
- Satisfied Charges ₹ 3.06 Cr
- Revenue Growth 18.07%
- Profit Growth -0.86%
- Ebitda 11.44%
- Net Worth 8.82%
- Total Assets 21.02%
About Anchor Pharma
Anchor Pharma Private Limited (APPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 28 April 1975 and has a history of 49 years and nine months. Its registered office is in Daman, Daman And Diu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹1.13 Cr. The company has closed loans amounting to ₹3.06 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kunal Mehta and Meenaxi Mehta serve as directors at the Company.
Company Details
-
Location
Daman, Daman And Diu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DD1975PTC000218
-
Company No.
000218
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Apr 1975
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Goa
Industry
Who are the key members and board of directors at Anchor Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunal Mehta
|
Director | 16-Aug-2001 | Current |
|
Meenaxi Mehta
|
Director Appointed In Casual Vacancy | 11-Dec-2016 | Current |
Financial Performance of Anchor Pharma.
Anchor Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.07% increase. The company also saw a slight decrease in profitability, with a 0.86% decrease in profit. The company's net worth moved up by a moderate rise of 8.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anchor Pharma?
In 2023, Anchor Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹11.30 M
₹30.62 M
Charges Breakdown by Lending Institutions
- Canara Bank : 1.00 Cr
- Others : 0.13 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jan 2023 | Others | ₹1.30 M | Open |
| 29 Jun 1991 | Canara Bank | ₹1.00 Cr | Open |
| 01 Apr 2000 | The Hongkong & Shanghai Banking Corporation Ltd. | ₹0.32 M | Satisfied |
| 02 Jun 1999 | Others | ₹3.03 Cr | Satisfied |
How Many Employees Work at Anchor Pharma?
Anchor Pharma has a workforce of 52 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anchor Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anchor Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
